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Primary graft dysfunction (PGD) after lung transplanta-
tion may result from ischemia reperfusion injury (IRI).
The innate immune response to IRI may be mediated
by Toll-like receptor and IL-1-induced long pentraxin-3
(PTX3) release. We hypothesized that elevated PTX3
levels were associated with PGD. We performed a
nested case control study of lung transplant recipi-
ents with idiopathic pulmonary fibrosis (IPF) or chronic
obstructive pulmonary disease (COPD) from the Lung
Transplant Outcomes Group cohort. PTX3 levels were
measured pretransplant, and 6 and 24 h postreperfu-
sion. Caseswere subjectswith grade 3 PGDwithin 72 h
of transplantation and controls were those without
grade 3 PGD. Generalized estimating equations and
multivariable logistic regression were used for analy-
sis. We selected 40 PGD cases and 79 non-PGD con-
trols. Plasma PTX3 level was associated with PGD in
IPF but not COPD recipients (p for interaction < 0.03).
Among patients with IPF, PTX3 levels at 6 and 24 h
were associated with PGD (OR = 1.6, p = 0.02 at 6 h;
OR = 1.4, p = 0.008 at 24 h). Elevated PTX3 levels were
associated with the development of PGD after lung
transplantation in IPF patients. Future studies evalu-
ating the role of innate immune activation in IPF and
PGD are warranted.
Key words: Idiopathic pulmonary fibrosis, long
pentraxin-3, lung transplantation, primary graft dys-
function
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Introduction
Ischemia reperfusion injury (IRI) plays a role in initiating pri-
mary graft dysfunction (PGD), activating and altering cel-
lular pathways involved in immune activation and leading
to an acute respiratory distress-like clinical phenomenon
(1–3). The role of innate immune activation after IRI in lung
transplant recipients is poorly understood.
Innate immune activation plays a role in the propagation of
IRI in transplanted solid organs (4–7). IRI involves Toll-like
receptor (TLR) signaling pathways, complement activation
and natural killer cell migration in cardiac transplantation
models and may lead to decreased allograft tolerance and
the later development of accelerated cardiac allograft vas-
culopathy (4,5). Innate immune activation as a result of IRI
has also been identified to contribute to renal and hepatic
allograft dysfunction (6,7).
Long pentraxin-3 (PTX3) is a member of a phylogeneti-
cally conserved group of acute phase reactants that are
involved in inflammation and innate immunity. A previous
study of plasma cytokines and PGD demonstrated that
plasma levels of other acute phase reactants, including
tumor necrosis factor alpha and interferon gamma, de-
creased after transplant and were not associated with risk
of PGD (8). PTX3 is produced at the site of inflammation
by cells implicated in the pathogenesis of PGD and has
been shown to be elevated in other pathologic conditions
related to both ischemia and inflammation, notably acute
myocardial infarction and acute lung injury (ALI) (9–11).
Abnormal activation of innate immunity in response to IRI
may be mediated by Toll-like receptors and IL-1-induced
PTX3 release. Consequently, higher PTX3 levels may play
a role in PGD pathogenesis or be a marker of innate im-
mune activation. We therefore hypothesized that elevated
PTX3 levels would be associated with PGD. In addition,
we sought to identify differences in the association of PGD
with PTX3 levels across the two most common indications
for lung transplantation, idiopathic pulmonary fibrosis (IPF)
and chronic obstructive pulmonary disease (COPD).
Materials and Methods
Subject selection
All study subjects were randomly selected from within the ongoing Lung
Transplant Outcomes Group (LTOG) cohort, a 13-center, prospective study
that has been described previously (12,13). A multicenter, nested case con-
trol study design was selected over a cohort study because of the signifi-
cant expense and sample volume required for evaluating PTX3 plasma con-
centrations. Cases and controls were randomly selected from the greater
than 1100 patients enrolled in the LTOG cohort. Blood samples were col-
lected from all cohort participants before transplant and at 6 and 24 h after
transplantation. Patient-level clinical data were collected prospectively and
plasma samples were centrifuged within 30 min and then stored at −80◦C
for biomarker measurement. The institutional review boards at each site
approved this study. Informed consent was obtained from each subject at
the time of enrollment in the cohort.
Subjects with grade 3 PGD that developed within 72 h of allograft reperfu-
sion were considered as cases. Subjects with grade 0–2 PGD but without
grade 3 PGD at any time after lung transplantation were considered as con-
trols. This case definition of PGD has been previously validated and used
extensively in the literature (14,15). Sensitivity analysis was performed us-
ing highest PGD grade within the first 72 h after allograft reperfusion as an
ordinal variable.
Patients with a reported predisposing diagnosis of IPF or COPD were eli-
gible for inclusion. To eliminate the possibility of small subgroups, ensure
the groups were comparable, and to allow for within diagnosis analyses,
the cases and controls were frequency matched for these predisposing di-
agnoses. We chose the two most common indications for transplantation
to minimize combinations of diagnoses and aid in matching.
PGD grade determination
PGD grades were assigned based on International Society for Heart and
Lung Transplant (ISHLT) guidelines as previously described (13). Chest X-
rays from immediately after transplant and from 24, 48 and 72 h after
transplant were examined independently by two trained physicians with
grades assigned for each radiograph (classification j = 0.95). As defined
by the ISHLT guidelines, grade 3 PGD is the presence of diffuse alveolar
infiltrates with a PaO2/FiO2 ratio <200 and the exclusion of secondary
causes (14,16).
Measurement of PTX3 concentration
Plasma PTX3 concentrations were determined in duplicate using a sand-
wich enzyme-linked immunosorbent assay (Alexis Biochemicals, Lausen,
Switzerland). The intraassay coefficient of variation for this assay was 5.7%.
All laboratory personnel were unaware of the PGD status of study subjects.
Statistical analysis
Study subject characteristics were compared using two sample t-tests or
Wilcoxon rank sum tests as appropriate. Proportions were compared us-
ing two-group proportion tests whereas characteristics with greater than
two variables were assessed with Kruskal–Wallis rank tests as described
previously (15). Primary analysis was performed using generalized estimat-
ing equations (GEE) to identify differences in PTX3 levels over time and
across study subjects. Secondary analyses included using Wilcoxon rank
sum tests across groups and multivariable logistic regression modeling.
Based on previous studies identifying differences in biomarker levels across
predisposing diagnoses, we a priori defined diagnosis leading to transplan-
tation as a possible effect modifier and performed diagnosis specific analy-
ses (15). Recipient and donor age, sex, race/ethnicity, cardiopulmonary by-
pass use, transplant surgical type, ischemic time, intraoperative pulmonary
artery systolic pressure (PASP), packed red blood cell (PRBC), platelet and
plasma transfusion volumes were included as possible confounders in mul-
tivariable logistic models. A change in odds ratio (OR), after inclusion of a
covariate, of greater than 20%was used to identify confounding. Sensitivity
analysis evaluating the association of PTX3 concentration with the highest
PGD grade on any day was preformed using ordinal logistic regression. A
p < 0.05 was predefined for statistical significance for all tests. We de-
fined the presence of effect modification a priori by a p < 0.1. All statistical
analyses were performed using Stata 11.1 software (STATA Corp., College
Station, TX, USA).
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Table 1: Subject characteristics stratified for PGD cases and non-PGD controls
Characteristics PGD (n = 40) Non-PGD (n = 79) p-Value
Recipient
Age (year) 55 (52, 58) 56 (53, 58) 0.7
Female 30% 46% 0.1
Race 0.1
Caucasian 80% 90%
African American 13% 5%
Hispanic 0% 4%
Asian 5% 1%
Other 3% 0%
Donor
Age (year) 34 (29, 38) 33 (30, 36) 0.7
Female 48% 43% 0.6
Race 0.2
Caucasian 73% 62%
African American 15% 22%
Hispanic 13% 9%
Asian 0% 6%
Other 0% 1%
Cause of death 0.9
Blunt trauma 3% 4%
Head trauma 30% 35%
Suicide 3% 0%
Stroke 48% 34%
Anoxia 0% 11%
Other 18% 15%
Recipient diagnosis 0.9
COPD 40% 41%
IPF 60% 59%
Transplant type, single 38% 38% 0.9
Use of cardiopulmonary bypass 54% 30% 0.01
Time on bypass (min) 235 (201, 270) 210 (184, 236) 0.2
Ischemic time (min) 308 (281, 334) 282 (262, 302) 0.1
Pulmonary artery systolic pressure (mmHg) 47 (40, 54) 41 (36, 46) 0.2
Packed red blood cells (mL) 1063 (675, 1450) 696 (538, 854) 0.04
Fresh frozen plasma (mL) 893 (702, 1084) 1062 (769, 1354) 0.3
Platelets (mL) 421 (99, 743) 228 (46, 411) 0.3
PGD is defined as any grade 3 PGD during first 72 h. Continuous variables are expressed as means with 95% confidence intervals,
whereas dichotomous and categorical variables are expressed as percentages, which may not exactly total 100% because of rounding.
Results
We included 40 PGD cases and 79 non-PGD controls (Ta-
ble 1). One control sample was excluded from analysis be-
cause of spurious results on the standard curve. A higher
percentage of PGD cases required cardiopulmonary by-
pass than controls (54% vs. 30%; p= 0.01) and PGD cases
received a larger volume of intraoperative PRBCs than con-
trols (1063 mL vs. 696 mL; p = 0.04), but cases and con-
trols were otherwise similar. There were 16 PGD cases
and 32 non-PGD controls with COPD, and 24 PGD cases
and 47 non-PGD controls with IPF. Although pretransplant
PTX3 levels were low compared to posttransplant levels in
all patients, pretransplant levels were significantly higher
in subjects with IPF (2.1 ng/mL; IQR 1.3, 7.0) compared to
subjects with COPD (0.8 ng/mL; IQR 0.5, 2.0; p < 0.001).
Among all enrolled subjects, GEE modeling identified a
nonsignificant difference in the trend of PTX3 levels across
all the three time points between cases and controls (b =
0.09, 95% CI −0.005, 0.2; p = 0.06; Figure 1A). The asso-
ciation between median PTX3 concentration and PGD dif-
fered according to predisposing diagnosis (p for interaction
<0.03). There was no significant difference in PTX3 con-
centration between COPD cases and controls at any time
point (all p > 0.08). GEE longitudinal modeling identified a
significant difference in the trend of PTX3 levels across all
the three time points between IPF cases and controls (b =
0.3; 95% CI 0.1, 0.5; p = 0.001) but not COPD cases and
controls (b = −0.2; 95% CI −0.5, 0.1; p = 0.2; Figures
1B and C). PTX3 levels were significantly higher in IPF pa-
tients with PGD compared to non-PGD IPF controls at 6 h
(45.7 ng/mL vs. 18.0 ng/mL; p= 0.02) and 24 h (88.9 ng/mL
vs. 22.7 ng/mL; p = 0.007) after reperfusion.
When subjects were analyzed according to diagnosis,
there was a significant association between PTX3 level
and the odds of PGD at 6 h (OR for each 50 ng/mL higher
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Figure 1: Longitudinal median PTX3 level across the pre-
transplant, 6-h posttransplant, and 24-h posttransplant time
points. (A) All study subjects, (B) subjects with IPF and (C) sub-
jects with COPD. Solid line represents PGD cases and dashed line
represents PGD-free controls. Error bars represent the 95% CI.
p-Value reported is from GEE modeling.
level= 1.6; 95%CI 1.1, 2.5; p= 0.02) and 24 h (OR for each
50 ng/mL higher level = 1.3; 95% CI 1.1, 1.7; p = 0.008)
for IPF patients but no association for subjects with COPD
at any time point (p > 0.30). Evaluation for possible con-
founding was performed on the IPF subgroup at 6 and 24 h
postreperfusion (Table 2). At 6 h, use of cardiopulmonary
bypass attenuated the association of PTX3 level with PGD.
There was no attenuation of this relationship by any covari-
ates for PTX3 levels measured at 24 h after reperfusion.
Surgical transplant type was similarly distributed among
both COPD and IPF recipients in this study and transplant
type was not found to be a confounder of the relationship
between PTX3 and PGD.
A sensitivity analysis using highest PGD grade on any day
as an ordinal outcome was performed. There was a signifi-
cant increase in PTX3 level at 24 h with increasing severity
of PGD (p = 0.048; Figure 2). This relationship was signif-
icant in the IPF subgroup (p = 0.006) but not the COPD
subgroup (p = 0.8).
Pulmonary hypertension and use of cardiopulmonary by-
pass have been previously identified as risk factors for
PGD (17). Although idiopathic pulmonary arterial hyperten-
sion patients were not included in this study, PASP among
study subjects ranged from 13 to 111 mmHg. Spearman
rank correlation revealed PASP was not significantly as-
sociated with PTX3 level before transplant (q = 0.15;
p = 0.1), or at 6 h (q = 0.14; p = 0.2) or 24 h (q = 0.19;
p = 0.06) after reperfusion.
Discussion
We found that elevated PTX3 levels were associated with
an increased risk of PGD in lung transplant recipients
with IPF but not COPD. Longitudinal analysis in the IPF
subgroup identified a significant difference in trend over
time of PTX3 levels in patients with PGD compared to
non-PGD controls. Furthermore, the relationships between
PGD and PTX3 levels in the IPF group were independent of
most donor, recipient and surgical characteristics, including
PASP, ischemic time and surgical transplant type, in mul-
tivariable modeling. This study provides clinical evidence
of a role for activation of innate immune pathways in the
pathogenesis of PGD after lung transplantation.
We identified a significant association between PTX3 level
and PGD in the IPF subgroup, with pretransplant PTX3 lev-
els being significantly higher in patients with IPF compared
to those with COPD. A registry study demonstrated recip-
ient pretransplant diagnosis of IPF to be independently
associated with increased risk for PGD when compared to
subjects with COPD (17). To our knowledge, there are no
previous studies investigating the role of PTX3 in IPF pa-
tients. We have previously shown that pretransplant CC16
levelswere higher in IPF recipients than in COPD recipients
and that posttransplant trends in CC16 levels differed in pa-
tients with IPF compared with other indications for trans-
plant (15). The IPF-specific association of elevated PTX3
level and PGDmay provide further evidence that posttrans-
plant biomarker profiles and important cellular pathways for
the development of PGD are likely dependent on pretrans-
plant diagnoses.
In the IPF subgroup, we identified a significant difference
between the longitudinal trend in PTX3 levels between
cases and controls, with significant univariate differences
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Table 2: Odds ratios for the development of Primary Graft Dysfunction in logistic regression models
Odds ratio per 50 ng/mL Odds ratio per 50 ng/mL
Model increase in PTX3, 6 h (95% CI) p-Value increase in PTX3, 24 h (95% CI) p-Value
Unadjusted base model (n = 119) 1.1 (0.9, 1.3) 0.5 1.1 (1.0, 1.3) 0.07
COPD only (n = 48) 0.8 (0.5, 1.3) 0.3 0.9 (0.7, 1.2) 0.5
IPF only (n = 71) 1.6 (1.1, 2.5) 0.02 1.4 (1.1, 1.7) 0.008
IPF adjusted for
Cardiopulmonary bypass (n = 71) 1.5 (1.0, 2.2) 0.09 1.3 (1.0, 1.6) 0.02
Transplant type (n = 71) 1.7 (1.1, 2.6) 0.02 1.4 (1.1, 1.8) 0.008
Recipient age (n = 71) 1.7 (1.1, 2.6) 0.02 1.4 (1.1, 1.7) 0.008
Recipient sex (n = 71) 1.6 (1.1, 2.5) 0.03 1.4 (1.1, 1.7) 0.008
Recipient race/ethnicity (n = 71) 1.6 (1.0, 2.4) 0.05 1.4 (1.1, 1.9) 0.01
Donor age (n = 70) 1.6 (1.0, 2.4) 0.03 1.4 (1.7, 1.7) 0.009
Donor mode of death (n = 66) 1.6 (1.0, 2.4) 0.04 1.3 (1.1, 1.7) 0.01
Donor sex (n = 71) 1.6 (1.1, 2.5) 0.03 1.4 (1.1, 1.8) 0.007
Donor race/ethnicity (n = 71) 1.7 (1.0, 2.7) 0.03 1.6 (1.1, 2.2) 0.01
Total ischemic time (n = 67) 1.9 (1.1, 3.5) 0.03 1.4 (1.1, 1.7) 0.02
PASP (n = 62) 1.5 (1.0, 2.3) 0.05 1.7 (1.1, 2.5) 0.01
Packed red blood cells (n = 66) 1.7 (1.1, 2.7) 0.03 1.4 (1.1, 1.7) 0.01
Platelets (n = 55) 1.9 (1.1, 3.5) 0.03 1.5 (1.1, 2.1) 0.009
Odds ratios for the development of primary graft dysfunction in logistic regression models per 50 ng/mL increase in PTX3. COPD =
chronic obstructive pulmonary disease; IPF = idiopathic pulmonary fibrosis; PASP = pulmonary arterial systolic pressure.
at 6 h and 24 h after transplant. This time course fits with
a previous study demonstrating PTX3 levels peaking at
7.5 h after CCU admission for myocardial infarction (9).
In addition, continued inflammatory insults can result in
prolongation of elevated PTX3 levels as seen in a cohort
study of critically ill medical intensive care unit patients
(18). In our study, whereas the most significant increase in
PTX3 occurred in patients with PGD, PTX3 levels increased
in all study subjects, regardless of outcome, implying an
association with IRI, even at lower levels of severity, in
patients without PGD. We do not have measurements of
PTX3 levels at later time points to further assess trends
over time.
There are several limitations to our study. First, there is the
potential for limited generalizability. Although our findings
weremost significant in the subpopulation of subjects with
IPF compared to those with COPD, other diagnoses were
not included in the study. Given the documented produc-
tion and release of PTX3 from vascular endothelial cells
and the significant association of recipient pulmonary hy-
pertension with PGD, elevated PTX3 plasma levels may
Figure 2: Median plasma PTX3
concentration 24 h after transplant
in all patients stratified by the high-
est PGD grade developing in the
first 72 h. Horizontal line indicates
median concentration. The upper and
lower limits of the box indicate the
interquartile range. p-Value reported
is determined from ordinal logistic
regression modeling.
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be important in PGD pathogenesis in other predisposing
diagnoses. In addition, whereas the association of PTX3
level and PGD was not significant in the COPD subgroup,
the small sample size in the COPD-only group may have
led to a false-negative result. In this study, we were unable
to identify a correlation between PASP and PTX3 level at
any time point. There is also the potential for PGD mis-
classification. Although the case control format limits the
ability to perform more extensive sensitivity analyses, an
analysis with an outcome of highest PGD grade in the
72 h after reperfusion demonstrated a significant associa-
tion between worsening grade from 0 to 3 and increased
PTX3 plasma level. As with previous biomarker studies,
given similar preoperative PTX3 levels between cases and
controls, it is not possible to define a causal relationship
of PTX3 production and release leading to PGD. However,
the concordance of PTX3 level with PGD supports a mech-
anistic role for innate immune activation in the develop-
ment of PGD. Although we controlled for identified con-
founders, we were unable to control for airway infection
or pre- and posttransplant bacterial colonization. Given the
integral role for PTX3 in innate immune responses and re-
sponse to infection, it is possible that PTX3 is a marker
for infection and that bacterial infection is the link with se-
vere PGD. PTX3 production by antigen presenting cells is
inducible by Pseudomonas aeruginosa and Aspergillus fu-
migatus and PTX3 has been shown to directly bind CMV
(19). However, the 3-day postoperative time frame for de-
veloping PGD makes clinically significant airway infection
an unlikely explanation for our findings, unless subclinical
infection preexisted in the donor. A previous study demon-
strated that positive donor gram stain is not associated
with the development of early postoperative pneumonia or
worsening oxygenation after transplant (20). Furthermore,
infection with Pseudomonas, Aspergillus and CMV occur
later in the posttransplant period and are associated with
increased rates of BOS, not PGD.
In summary, we identified elevated PTX3 plasma concen-
trations to be strongly associated with postlung transplant
PGD in patientswith IPF. This provides support for amecha-
nistic role for innate immune activation in the development
of severe PGD. Elucidating differences in innate immune
activation in IPF compared to COPD in lung transplant re-
cipients is an area of future study.
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